Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.

Abstract

OBJECTIVES We aimed to evaluate the efficacy of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). METHODS Medline, Embase, Cochrane Central Register of Controlled Trials, and Web of Science were searched until April 18, 2014. RESULTS Seven randomized controlled trials and 2956 patients met the… (More)
DOI: 10.1097/MPA.0000000000000310

Topics

  • Presentations referencing similar topics